This study is testing a topical spray called ELU42 for people with diabetic foot ulcers (DFUs). ELU42 is designed to help wounds heal by affecting how cells communicate (Wnt signaling). Researchers want to see if ELU42 is safe and how well it works to reduce the size of DFUs. You might be able to join if you are 18-75 years old, have type 1 or 2 diabetes, and have a DFU that is Wagner grade 1 or 2, between 1 and 8 square centimeters in size, and has been present for 4 to 52 weeks. The main goal is to measure how much the ulcer area shrinks by week 4 and week 6. The study plans to enroll 15 participants, but the current recruitment status is unclear.

Study design

This is an early-phase, single-arm, open-label study, meaning all participants will receive ELU42 and both you and the study team will know what treatment you are getting. It plans to enroll 15 adults.

What's involved

You would apply ELU42 topical spray to your ulcer for up to six weeks. If your wound reopens, you might restart treatment for another six weeks, up to a maximum of 18 applications. You will have safety assessments including blood tests (CBC, CMP), ECGs, and nutritional and reproductive safety monitoring.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome measures how much the ulcer area shrinks at week 4 and week 6.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.